Biogen (BIIB, $291.61) shares slump, amidst reports of patient death in Eisai Alzheimer's death
Biogen shares plunged on Monday, following reports that a woman who participated in a trial of the drugmaker's developing Alzheimer's treatment died due to a brain hemorrhage. The company is developing the drug with Eisai Co.
According to Science.org, the case involved a 65-year-old woman who died of a massive brain hemorrhage following a stroke and a type of brain swelling and bleeding in a trial of Eisai. The report mentioned that the bleeding started after the patient received an anti-clotting drug.
Biogen and Eisai have published very limited data from the trial. More results are expected to be presented at a conference this week.
BIIB in -1.05% downward trend, falling for three consecutive days on June 30, 2025
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BIIB declined for three days, in of 338 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on BIIB as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BIIB just turned positive on July 02, 2025. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .
BIIB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 138 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIIB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.110) is normal, around the industry mean (5.632). P/E Ratio (26.955) is within average values for comparable stocks, (48.974). BIIB's Projected Growth (PEG Ratio) (8.807) is slightly higher than the industry average of (3.004). Dividend Yield (0.000) settles around the average of (0.161) among similar stocks. P/S Ratio (3.181) is also within normal values, averaging (3.643).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders
Industry PharmaceuticalsMajor
Advertisement